Literature DB >> 28838713

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.

Tomoko Funazo1, Takashi Nomizo2, Young Hak Kim2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28838713     DOI： 10.1016/j.jtho.2017.04.027

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  26 in total

Review 1.  Liver metastases.

Authors:  Diamantis I Tsilimigras; Pnina Brodt; Pierre-Alain Clavien; Ruth J Muschel; Michael I D'Angelica; Itaru Endo; Rowan W Parks; Majella Doyle; Eduardo de Santibañes; Timothy M Pawlik
Journal:  Nat Rev Dis Primers       Date:  2021-04-15       Impact factor: 52.329

2.  Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis.

Authors:  Yangyun Huang; Lihuan Zhu; Tianxing Guo; Wenshu Chen; Zhenlong Zhang; Wujin Li; Xiaojie Pan
Journal:  Hum Vaccin Immunother       Date:  2020-10-20       Impact factor: 3.452

3.  Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.

Authors:  Wenjie Liu; Gengwei Huo; Peng Chen
Journal:  Front Immunol       Date:  2022-06-21       Impact factor: 8.786

4.  The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.

Authors:  Rui Kitadai; Yusuke Okuma; Taiki Hakozaki; Yukio Hosomi
Journal:  J Cancer Res Clin Oncol       Date:  2019-12-11       Impact factor: 4.553

5.  Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials.

Authors:  Qing Yin; Longguo Dai; Ruizhu Sun; Ping Ke; Liya Liu; Bo Jiang
Journal:  Cancer Res Treat       Date:  2021-10-25       Impact factor: 5.036

Review 6.  Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.

Authors:  Amanda J Oliver; Peter K H Lau; Ashleigh S Unsworth; Sherene Loi; Phillip K Darcy; Michael H Kershaw; Clare Y Slaney
Journal:  Front Immunol       Date:  2018-01-31       Impact factor: 7.561

7.  Abdominal lymph node metastasis by lymphatic spread through the thoracic duct in patients with non-small-cell lung cancer.

Authors:  Wookyung Ryu; Myoung Kyu Lee; Mi Hwa Park; In Young Hyun; Minkyung Lee; Eun-Ji No; Seok Joong Yong; Jung Soo Kim; Jun Hyeok Lim; Jeong-Seon Ryu
Journal:  Thorac Cancer       Date:  2021-05-25       Impact factor: 3.500

8.  Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma.

Authors:  Yanan Zheng; Rajesh Narwal; ChaoYu Jin; Paul G Baverel; Xiaoping Jin; Ashok Gupta; Yong Ben; Bing Wang; Pralay Mukhopadhyay; Brandon W Higgs; Lorin Roskos
Journal:  Clin Pharmacol Ther       Date:  2018-01-17       Impact factor: 6.875

9.  Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?

Authors:  Kenichi Suda; Tetsuya Mitsudomi
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

10.  Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer.

Authors:  Takahiro Ishii; Akihito Kawazoe; Akinori Sasaki; Saori Mishima; Sawada Kentaro; Yoshiaki Nakamura; Daisuke Kotani; Yasutoshi Kuboki; Hiroya Taniguchi; Takashi Kojima; Toshihiko Doi; Takayuki Yoshino; Takeshi Kuwata; Genichiro Ishii; Kohei Shitara
Journal:  Ther Adv Med Oncol       Date:  2020-07-17       Impact factor: 8.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.